Xoma Corp. and partner Pfizer Inc. finally threw in the towel in their efforts to make XOMA's E5 monoclonal antibody work in sepsis, providing a reminder of earlier spectacular letdowns against the bacterial infection.

Pfizer (New York, N.Y.) and XOMA (Berkeley, Calif.) halted their third Phase III trial with E5 after an interim analysis by a review board indicated that the compound was unlikely to show significant results.